Charts

05 Feb, 2023

News

02 Feb, 2023
Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, “Murchinson” or “we”), which holds approximately 5.1% of the outstanding shares of Nano Dimension Ltd. (NASDAQ: NNDM) (“Nano Dimension” or the “Company”), today issued the below open letter to its fellow shareholders following its unsuccessful attempts to engage with the Company’s Board of Directors (the “Board”) and management.
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on February 14, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert “Willie” Mays, Executive Vice President Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company’s recent clinical and operational progress, upcoming milestones and vision for the year.
30 Jan, 2023
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its participation in two upcoming conferences, the International Stroke Conference 2023 (ISC) from February 8-10, 2023 in Houston, TX and BioProcess International US West from February 27-March 2, 2023 in San Diego, CA. Any registered attendees interested in meeting with Athersys at either conference can contact Ellen Gurley at [email protected] to set up a meeting.
12 Jan, 2023
If the company's stock price stays above $1 for 10 consecutive business days, Athersys will regain compliance with a Nasdaq listing requirement.
11 Jan, 2023
Gainers Ontrak (NASDAQ:OTRKP) shares moved upwards by 44.1% to $0.92 during Wednesday's regular session. The current volume of 122.0K ...
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today their participation in two January conferences, Advanced Therapies Week presented by Phacilitate from January 17-20, 2023 in Miami, FL and the 2nd Allogeneic Cell Therapies Summit Europe from January 30-February 1, 2023 in London, UK.
10 Jan, 2023
For most of the last year, clinical-stage Athersys has been cutting costs to preserve its capital while looking for new partners to help launch its adult stem cell therapy.
09 Jan, 2023
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2). MultiStem is a proprietary off-the-shelf stem cell product in late-stage clinical trials for acute ischemic stroke, as well as trauma and other inflammatory conditions.
06 Jan, 2023
Athersys Inc., the regenerative medicine startup in Cleveland, has appointed a biotech and drug commercialization professional to its board of directors. Joseph Nolan is CEO of Jaguar Gene Therapy LLC in Lake Forest, Illinois, Athersys said in a statement. "Joe is a strong addition to our board, bringing more than 30 years of experience managing high-value global pipelines, launching multiple successful drugs and optimizing large-scale commercial operations," Ismail Kola, chairman of the Athersys board, in the company's statement.
05 Jan, 2023
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Joseph “Joe” Nolan to its Board of Directors, effective January 4, 2023. Mr. Nolan is an experienced biotechnology and pharmaceutical executive who currently serves as Chief Executive Officer of Jaguar Gene Therapy, LLC. With this appointment, Athersys has five Directors, four of whom are independent.
28 Dec, 2022
Athersys, Inc. (NASDAQ:ATHX) Q3 2022 Earnings Call Transcript November 15, 2022 Athersys, Inc. beats earnings expectations. Reported EPS is $-1.15, expectations were $-1.96. Operator: Good morning. My name is Devon and I will be your conference operator today. At this time, I would like to welcome everyone to the Athersys Third Quarter 2022 Results Conference […]
23 Dec, 2022
According to data from Benzinga Pro, during Q3, Athersys's (NASDAQ:ATHX) reported sales totaled $65 thousand. Despite a 42.2% increase ...
15 Dec, 2022
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares rose 74.7% to $0.4104 in pre-market trading after declining 4% on ...
29 Nov, 2022
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! It's time for another dive into the biggest pre-market stock movers with the shares rising and falling on Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares rose 26.3% to $0.7994 in pre-market trading after the company received FDA 510K ...
15 Nov, 2022
For months, Athersys has been restructuring its operations and trying to raise cash to complete the testing and commercialization of MultiStem.
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and nine months ended September 30, 2022 and provided a business update.
11 Nov, 2022
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its participation in two November conferences, the Challenges and Opportunities for Mesenchymal Stem Cells digital conference being held November 17-18, 2022 and A.G.P.’s Biotech Conference on November 30, 2022.
10 Nov, 2022
Athersys, Inc. (Nasdaq: ATHX) today announced the closing of its previously announced confidentially marketed public offering with healthcare-focused U.S. institutional investors for the purchase of 5,004,545 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 10,009,090 of common stock at a combined purchase price of $1.10, resulting in gross proceeds of approximately $5.5 million before deducting placement agent fees and other offering expenses. The warrants have an exercise price of $1.10 per share, are exercisable immediately following the date of issuance and will expire five years from the date of issuance.
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it intends to file its quarterly report on Form 10-Q for the three months ended September 30, 2022 with the U.S. Securities and Exchange Commission (SEC) after market close on Monday, November 14, 2022, issue a news release reporting those financial results and recent business highlights before market open on Tuesday, November 15, 2022, and hold a conference call at 11:00 a.m. Eastern Time on Tuesday, November 15, 2022.
Gainers Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares climbed 212.8% to close at $12.51 on Wednesday after partner Ipsen ...
09 Nov, 2022
22:35
Seeking Alpha
U.S. stocks traded lower toward the end of trading , with the Nasdaq Composite dropping 200 points on Wednesday. The Dow traded down ...
Gainers Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares jumped 219% to $12.80 after partner Ipsen reported Onivyde met its ...
U.S. stocks traded lower midway through trading as investors focused on the outcome of the midterm elections. The Dow traded down ...
On Nov. 4, the company's accounts receivable — owed mostly to its primary contract manufacturer — outweighed its cash at a ratio of about 3:1.
Athersys, Inc. (Nasdaq: ATHX) (“Athersys” or the “Company”) today announced the pricing of its previously announced "best efforts" public offering of 5,004,545 shares of common stock (or common stock equivalents) and warrants to purchase 10,009,090 shares of common stock at a combined price of $1.10 per share and accompanying warrant for aggregate gross proceeds of approximately $5.5 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $1.10 per share, will be exercisable immediately following the date of issuance and will expire five years from the date of issuance.
Gainers Merrimack Pharmaceuticals (NASDAQ:MACK) shares rose 180.0% to $11.2 during Wednesday's pre-market session. The ...
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of ...
08 Nov, 2022
Gainers NeoGenomics (NASDAQ:NEO) stock increased by 29.1% to $9.17 during Tuesday's regular session. Trading volume for this ...
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from ...
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares rose 49.1% to $3.22 during Tuesday's pre-market session. The ...
Gainers Ocuphire Pharma, Inc. (NASDAQ: OCUP) shares rose 27.8% to $2.67 in pre-market trading. Ocuphire Pharma entered into a ...
07 Nov, 2022
For months, the Cleveland-based regenerative medicine company has been restructuring its operations and trying to raise the cash it needs to complete the testing and commercialization of its adult stem cell therapy, MultiStem.
Athersys, Inc. (Nasdaq: ATHX) (“Athersys” or the “Company”) today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase common stock, subject to market and other conditions, in a public offering. All of the securities to be sold in the offering are to be offered by Athersys. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
31 Oct, 2022
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) jumped 153.9% to close at $3.30 on Friday. Aeglea BioTherapeutics, Inc. (NASDAQ: ...
25 Oct, 2022
Athersys, Inc. (Nasdaq: ATHX) will be hosting a conference call on Thursday, November 10, 2022, at 4:30 PM Eastern Time to review its third quarter 2022 financial results.
06 Oct, 2022
Gainers Chardan NexTech Acquisition 2 Corp. (NASDAQ: CNTQ) shares surged 102.6% to close at $21.54 on Wednesday. Nauticus ...
05 Oct, 2022
Losers KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) shares dipped 58.9% to close at $5.85 on Tuesday after ...
04 Oct, 2022
Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday. Connexa Sports Technologies ...
U.S. stocks traded higher, with the Dow Jones gaining more than 700 points on Tuesday. Here are some big stocks recording losses in ...
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today their participation in two October conferences, the 2022 Cell & Gene Meeting on the Mesa on October 11-13, 2022 and the 14th World Stroke Congress on October 26-29, 2022.
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it ...
03 Oct, 2022
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37. SAI.TECH Global Corporation (NASDAQ: SAI) gained 43.4% ...
30 Sep, 2022
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on October 6, 2022 at 4:00 pm Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert “Willie” Mays, Executive Vice President Regenerative Medicine and Head of Neuroscience, will provide an overview of the company’s accomplishments since its recently announced restructuring.
27 Sep, 2022
Gainers LAVA Therapeutics N.V. (NASDAQ: LVTX) shares climbed 97.5% to close at $4.74 on Monday after the company and Seagen Inc ...
26 Sep, 2022
Gainers LAVA Therapeutics N.V. (NASDAQ: LVTX) shares jumped 97% to $4.71 after the company and Seagen Inc (NASDAQ: SGEN) ...
U.S. stocks traded mixed, with the Dow Jones dropping around 80 points on Monday. Here are some big stocks recording losses in ...
Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday. Kiromic BioPharma, ...
23 Sep, 2022
U.S. stocks extended losses toward the end of trading, with the Dow Jones dropping to a fresh low for the year. The Dow traded down ...
Gainers Kiromic BioPharma (NASDAQ:KRBP) stock rose 71.7% to $0.44 during Friday's regular session. As of 13:30 EST, Kiromic ...
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company ...
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 200 points on Friday. The Dow traded ...
Athersys Inc (NASDAQ: ATHX) shares are trading higher by 31.63% to $1.54Friday morningafter the company announced it entered ...
U.S. stocks traded lower, with the Dow Jones dropping around 400 points on Friday. Here are some big stocks recording gains in ...
25 Aug, 2022
15 Aug, 2022
04 Aug, 2022
25 Jul, 2022
20:29
Seeking Alpha
05 May, 2022
16:14
Seeking Alpha
04 May, 2022
13:40
Seeking Alpha
18 Apr, 2022
15 Mar, 2022
14 Mar, 2022
21:35
Seeking Alpha

Related Articles